Updated Jul 16, 2026 · Last SEC filing 2026-07-13
Amylyx Pharmaceuticals, Inc. (AMLX) has filed 7 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-13. 2 Form 8-K material event filings were reported by AMLX in the last 90 days. 1 Form 144 notices of proposed sale were filed for AMLX stock. InsiderAlpha tracks every AMLX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001658551 |
| Form 4 filings (90d) | 7 |
|---|---|
| Form 8-K filings (90d) | 2 |
| Form 144 notices (90d) | 1 |
| Latest Form 4 filing | 2026-07-13 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mazzariello Gina | Chief Legal Officer | S — Open-market sale [10b5-1] | 15.0K | $17.61 | $264K | SEC | |
| Mazzariello Gina | Chief Legal Officer | S — Open-market sale [10b5-1] | 15.0K | $18.32 | $275K | SEC | |
| Firestone Karen | Insider | P — Open-market purchase | 3.8K | $13.51 | $51K | SEC | |
| Mazzariello Gina | Chief Legal Officer | A — Grant or award | 74.7K | $0.00 | — | SEC | |
| Cohen Joshua B | Co-Chief Executive Officer | A — Grant or award | 248.9K | $0.00 | — | SEC | |
| Klee Justin B. | Co-Chief Executive Officer | A — Grant or award | 248.9K | $0.00 | — | SEC | |
| Bedrosian Camille L | Chief Medical Officer | A — Grant or award | 96.0K | $0.00 | — | SEC | |
| FRATES JAMES M | Chief Financial Officer | A — Grant or award | 96.0K | $0.00 | — | SEC | |
| Bedrosian Camille L | Chief Medical Officer | S — Open-market sale | 6.5K | $14.58 | $94K | SEC | |
| FRATES JAMES M | Chief Financial Officer | S — Open-market sale | 7.9K | $14.52 | $115K | SEC | |
| Mazzariello Gina | Chief Legal Officer | S — Open-market sale | 6.8K | $14.52 | $99K | SEC | |
| Klee Justin B. | Co-Chief Executive Officer | S — Open-market sale | 29.3K | $14.47 | $424K | SEC | |
| Cohen Joshua B | Co-Chief Executive Officer | S — Open-market sale | 29.3K | $14.48 | $424K | SEC | |
| Mazzariello Gina | Chief Legal Officer | S — Open-market sale | 3.4K | $14.14 | $48K | SEC | |
| Mazzariello Gina | Chief Legal Officer | S — Open-market sale | 3.4K | $14.65 | $51K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Amylyx Pharmaceuticals, Inc. (AMLX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Mazzariello Gina | 2 | $539K |
| Firestone Karen | 2 | $51K |
| MILNE GEORGE M JR | 1 | — |
| FONTEYNE PAUL R. | 1 | — |
| Zeiher Bernhardt G | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AMLX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live AMLX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.